A educação especial na rede municipal de ensino de Canoas- RS: conexões entre as normativas e as práticas cotidianas

O presente estudo teve como objetivo analisar as principais normativas nacionais referentes à Educação Especial em uma perspectiva inclusiva buscando estabelecer conexões com as normativas do município de Canoas e como objetivo específico: analisar de quais formas as normativas definidas pelo município de Canoas se efetivam nas práticas cotidianas quanto aos quesitos: Atendimento Educacional Especializado, avaliação e identificação e profissional de apoio. As questões norteadoras foram as indagações: Quais ações ou fatores influenciam na efetivação ou não das resoluções municipais? Como as políticas de Educação Especial estão sendo compreendidas pelos professores, gestores do município? Há indicações de adesão, divergência ou resistência por parte do município em relação às normativas federais? Esta pesquisa assume um caráter qualitativo, onde analisei os dados disponibilizados pela Secretaria Municipal de Educação e complementados com entrevistas semiestruturadas com perguntas abertas a um gestor do setor de inclusão escolar e dois professores do Atendimento Educacional Especializado. Alguns autores foram escolhidos como base teórica no que tange às Políticas da Educação Especial na Perspectiva Inclusiva: Claudio Roberto Baptista, Katia Regina Moreno Caiado, Cláudia Freitas, Clarissa Hass, Denise Meyrelles de Jesus, Fabiane Bridi, Maria Teresa Mantoan, José Geraldo Bueno, Rosângela Gavioli Prieto, entre outros. Bem como as normativas da Educação e da Educação Especial, dentre elas: Constituição Federal de 1988; Lei de Diretrizes e Bases da Educação Nacional de 1996, Política Nacional de Educação Especial na Perspectiva Inclusiva (2008), Resolução 04 de 2009, Nota técnica 04 de 2014 e Lei Brasileira de Inclusão (2015). A análise de dados foi organizada em três eixos: Atendimento educacional Especializado, Avaliação e identificação e Profissional de Apoio. Os resultados dos levantamentos de dados demonstram um aumento expressivo no número de matrículas de alunos da Educação Especial. As evidências das entrevistas apontam que a rede municipal de ensino tem buscado manter-se consoante às normativas federais, e há elementos que demonstram avanços nas ações de inclusão escolar com a valorização dos profissionais do magistério, formação especifica do professor que atua no AEE e profissionais de apoio em todas as escolas. Contudo, há grandes desafios no processo de efetivação da inclusão escolar.This study aimed to analyze the main national regulations regarding Special Education in an inclusive perspective, seeking to establish connections with the regulations in the city of Canoas, with the specific objective of analyzing in which ways the regulations defined by the city are effective in everyday practices for the following questions: Specialized Educational Assistance, evaluation and identification, and support professionals. The guiding questions were these: Which actions or factors influence the effectiveness or not of municipal resolutions? How are Special Education policies being understood by teachers and managers of the city? Are there signs of adherence, divergence or resistance of the city in relation to federal regulations? This research has a qualitative character, in which we analyzed the data made available by the Municipal Department of Education and complemented with semi-structured interviews with essay questions for a manager of the school inclusion sector and two teachers of the Specialized Educational Assistance. Some authors were chosen as the theoretical basis for the Special Education Policies in the Inclusive Perspective: Claudio Roberto Baptista, Katia Regina Moreno Caiado, Cláudia Freitas, Clarissa Hass, Denise Meyrelles de Jesus, Fabiane Bridi, Maria Teresa Mantoan, José Geraldo Bueno, Rosângela Gavioli Prieto, among others. As well as the regulations of Education and Special Education, such as: the Federal Constitution of 1988; the National Education Policy and Guidelines Act, from 1996; the National Policy on Special Education in the Inclusive Perspective, from 2008; the Resolution 04, from 2009; the Technical Note 04, from 2014; and the Brazilian Inclusion Law, from 2015. The data analysis was organized in three axes: Specialized Educational Assistance, Evaluation and identification, and Support professionals. The results of the data surveys showed a significant increase in the enrollment of Special Education students. The evidence from the interviews shows that the municipal education network has sought to keep up with federal regulations, implementing the actions of school inclusion with the appreciation of teaching professionals, specific training of teachers who work in the ESA and support professionals in all schools. However, there are major challenges in the process of achieving school inclusion

Tecnologias educacionais acessíveis para apoiar o ensino de matemática: uma revisão sistemática de literatura

Apresentamos uma Revisão Sistemática de Literatura (RSL) sobre o uso de Arquiteturas Pedagógicas (A.P) e tecnologias para apoiar o ensino de matemática a educandos com Transtorno do Espectro Autista e Deficiência Intelectual. A metodologia se baseou no protocolo de RSL consolidado por Kitchenham (2004). Utilizou-se como corpus de informação os periódicos científicos que atendiam aos critérios de inclusão e exclusão definidos no protocolo de pesquisa. Foram encontrados 361 trabalhos, desses, 21 foram selecionados e analisados, de forma a responder as questões de perguntas estabelecidas. Conclui-se que ainda é incipiente o número de pesquisas sobre o uso de tecnologias para apoiar a construção de conhecimentos matemáticos para sujeitos com TEA e/ou Deficiência Intelectual. Ao tratarmos especificamente do ensino de álgebra mediados por tecnologias os resultados foram mais escassos, sendo localizado apenas um trabalho nesta área de ensino e os demais tratava-se das quatro operações matemáticas

O Uso de Laboratórios Virtuais por educandos com Deficiência Visual/ Cegos no Ensino de Ciências: Uma Revisão Sistemática de Literatura

O uso de laboratórios virtuais de aprendizagem é cada vez mais adotado como uma ferramenta para apoiar as aprendizagens, por permitir que os sujeitos possam experimentar diversas situações que favoreçam seu desenvolvimento. Ao referirmos aos estudantes com deficiência visual e/ou cegueira, estas práticas tornam-se desafiadoras.Diante disso, apresentamos uma Revisão Sistemática de Literatura (RSL) sobre o uso de Laboratórios Virtuais em aulas de ciências com a participação desses educandos. Foi utilizado o protocolo de RSL consolidado por Kitchenham (2004) como base metodológica. As informações e dados foram encontrados em periódicos científicos conforme os critérios de inclusão e exclusão pré-estabelecidos no protocolo de pesquisa. Localizamos 320 trabalhos, desses, 11 foram selecionados e analisados, de forma a responder as questões estabelecidas. Conclui-se que são incipientes as pesquisas sobre LV para apoiar o ensino de Ciências para o público considerado

Arquitetura pedagógica debate de teses: critérios para seleção de teses

Em um Debate de Teses, os participantes discutem, de forma estruturada, sobre afirmações acerca de um determinado tema. Neste estudo analisamos as justificativas para selecionar teses produzidas para um debate, realizado para consolidar as aprendizagens sobre os tópicos estudados em uma disciplina. As teses foram selecionadas de uma lista elaborada pelos estudantes, usando critérios baseados em suas experiências. A análise identificou quatro categorias com seus respectivos indicadores. Na sequência, os critérios foram categorizados e refinados para orientar a seleção de teses sobre tópicos em geral

A time-resolved proteomic and prognostic map of COVID-19.

COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. We characterized the time-dependent progression of the disease in 139 COVID-19 inpatients by measuring 86 accredited diagnostic parameters, such as blood cell counts and enzyme activities, as well as untargeted plasma proteomes at 687 sampling points. We report an initial spike in a systemic inflammatory response, which is gradually alleviated and followed by a protein signature indicative of tissue repair, metabolic reconstitution, and immunomodulation. We identify prognostic marker signatures for devising risk-adapted treatment strategies and use machine learning to classify therapeutic needs. We show that the machine learning models based on the proteome are transferable to an independent cohort. Our study presents a map linking routinely used clinical diagnostic parameters to plasma proteomes and their dynamics in an infectious disease

Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study

Purpose: Adequate patient allocation is pivotal for optimal resource management in strained healthcare systems, and requires detailed knowledge of clinical and virological disease trajectories. The purpose of this work was to identify risk factors associated with need for invasive mechanical ventilation (IMV), to analyse viral kinetics in patients with and without IMV and to provide a comprehensive description of clinical course. Methods: A cohort of 168 hospitalised adult COVID-19 patients enrolled in a prospective observational study at a large European tertiary care centre was analysed. Results: Forty-four per cent (71/161) of patients required invasive mechanical ventilation (IMV). Shorter duration of symptoms before admission (aOR 1.22 per day less, 95% CI 1.10-1.37, p < 0.01) and history of hypertension (aOR 5.55, 95% CI 2.00-16.82, p < 0.01) were associated with need for IMV. Patients on IMV had higher maximal concentrations, slower decline rates, and longer shedding of SARS-CoV-2 than non-IMV patients (33 days, IQR 26-46.75, vs 18 days, IQR 16-46.75, respectively, p < 0.01). Median duration of hospitalisation was 9 days (IQR 6-15.5) for non-IMV and 49.5 days (IQR 36.8-82.5) for IMV patients. Conclusions: Our results indicate a short duration of symptoms before admission as a risk factor for severe disease that merits further investigation and different viral load kinetics in severely affected patients. Median duration of hospitalisation of IMV patients was longer than described for acute respiratory distress syndrome unrelated to COVID-19

Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients

Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed to assess whether CP administered during the first week of symptoms reduced the disease progression or risk of hospitalization of outpatients. Two multicenter, double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when = 50 years and symptomatic for <= 7days were included. The intervention consisted of 200-300mL of CP with a predefined minimum level of antibodies. Primary endpoints were a 5-point disease severity scale and a composite of hospitalization or death by 28 days. Amongst the 797 patients included, 390 received CP and 392 placebo; they had a median age of 58 years, 1 comorbidity, 5 days symptoms and 93% had negative IgG antibody-test. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The odds ratio (OR) of CP for improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311); OR for hospitalization or death was 0.919 (CI 0.592-1.416). CP effect on hospital admission or death was largest in patients with <= 5 days of symptoms (OR 0.658, 95%CI 0.394-1.085). CP did not decrease the time to full symptom resolution

Les droits disciplinaires des fonctions publiques : « unification », « harmonisation » ou « distanciation ». A propos de la loi du 26 avril 2016 relative à la déontologie et aux droits et obligations des fonctionnaires

The production of tt‾ , W+bb‾ and W+cc‾ is studied in the forward region of proton–proton collisions collected at a centre-of-mass energy of 8 TeV by the LHCb experiment, corresponding to an integrated luminosity of 1.98±0.02 fb−1 . The W bosons are reconstructed in the decays W→ℓν , where ℓ denotes muon or electron, while the b and c quarks are reconstructed as jets. All measured cross-sections are in agreement with next-to-leading-order Standard Model predictions.The production of $t\overline{t}$, $W+b\overline{b}$ and $W+c\overline{c}$ is studied in the forward region of proton-proton collisions collected at a centre-of-mass energy of 8 TeV by the LHCb experiment, corresponding to an integrated luminosity of 1.98 $\pm$ 0.02 \mbox{fb}^{-1}. The $W$ bosons are reconstructed in the decays $W\rightarrow\ell\nu$, where $\ell$ denotes muon or electron, while the $b$ and $c$ quarks are reconstructed as jets. All measured cross-sections are in agreement with next-to-leading-order Standard Model predictions

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe